Steven D. Harr
2015 - Juno Therapeutics
In 2015, Steven D. Harr earned a total compensation of $3.4M as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, a 11% decrease compared to previous year.
Compensation breakdown
| Bonus | $112,000 |
|---|---|
| Non-Equity Incentive Plan | $208,000 |
| Option Awards | $2,701,300 |
| Salary | $400,000 |
| Total | $3,421,300 |
Harr received $2.7M in option awards, accounting for 79% of the total pay in 2015.
Harr also received $112K in bonus, $208K in non-equity incentive plan and $400K in salary.
Rankings
In 2015, Steven D. Harr's compensation ranked 2,674th out of 13,638 executives tracked by ExecPay. In other words, Harr earned more than 80.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,674 out of 13,638 | 80th |
Division Manufacturing | 945 out of 5,190 | 82nd |
Major group Chemicals And Allied Products | 345 out of 1,854 | 81st |
Industry group Drugs | 270 out of 1,528 | 82nd |
Industry Biological Products, Except Diagnostic Substances | 48 out of 254 | 81st |
Source: SEC filing on April 21, 2017.
Harr's colleagues
We found four more compensation records of executives who worked with Steven D. Harr at Juno Therapeutics in 2015.
News
Sana Biotechnology Former Executive Vice President and President, Research and Development Douglas Williams receives $3M in 2023
April 26, 2024
Sana Biotechnology General Counsel Bernard Cassidy receives $4M in 2022
April 28, 2023
Sana Biotechnology Chief Medical Officer Sunil Agarwal receives $1.9M in 2021
April 26, 2022